Lexicon Pharmaceuticals, Inc. (LXRX)
USD 0.45
(2.46%)
USD 0.45
(2.46%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 83.59 Million USD | 834.17% |
| 2022 | 8.94 Million USD | 114.48% |
| 2021 | -61.78 Million USD | 45.54% |
| 2020 | -113.45 Million USD | -153.98% |
| 2019 | 210.17 Million USD | 147.41% |
| 2018 | 84.95 Million USD | 230.46% |
| 2017 | -65.11 Million USD | 73.43% |
| 2016 | -245.05 Million USD | 41.03% |
| 2015 | -415.54 Million USD | -79.37% |
| 2014 | -231.67 Million USD | -116.01% |
| 2013 | -107.25 Million USD | 46.31% |
| 2012 | -199.75 Million USD | 22.21% |
| 2011 | -256.79 Million USD | -1271.42% |
| 2010 | -18.72 Million USD | 44.25% |
| 2009 | -33.59 Million USD | 39.35% |
| 2008 | -55.38 Million USD | -756.56% |
| 2007 | 8.43 Million USD | 329.92% |
| 2006 | 1.96 Million USD | -86.89% |
| 2005 | 14.97 Million USD | -34.97% |
| 2004 | 23.01 Million USD | 190.02% |
| 2003 | -25.57 Million USD | 27.69% |
| 2002 | -35.36 Million USD | -53.43% |
| 2001 | -23.04 Million USD | 34.08% |
| 2000 | -34.96 Million USD | -417.86% |
| 1999 | 11 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 70.05 Million USD | 618.55% |
| 2024 Q1 | 9.75 Million USD | -88.34% |
| 2023 FY | 83.59 Million USD | 834.17% |
| 2023 Q4 | 83.59 Million USD | -1.51% |
| 2023 Q1 | 28.29 Million USD | 216.21% |
| 2023 Q3 | 84.88 Million USD | 2492.64% |
| 2023 Q2 | 3.27 Million USD | -88.43% |
| 2022 Q3 | 11.79 Million USD | 196.93% |
| 2022 Q2 | 3.97 Million USD | 111.68% |
| 2022 Q1 | -34 Million USD | 44.96% |
| 2022 FY | 8.94 Million USD | 114.48% |
| 2022 Q4 | 8.94 Million USD | -24.12% |
| 2021 FY | -61.78 Million USD | 45.54% |
| 2021 Q3 | -77.91 Million USD | 26.35% |
| 2021 Q4 | -61.78 Million USD | 20.7% |
| 2021 Q1 | -84.96 Million USD | 25.11% |
| 2021 Q2 | -105.79 Million USD | -24.52% |
| 2020 Q3 | -31.37 Million USD | -119.75% |
| 2020 Q2 | 158.87 Million USD | -16.22% |
| 2020 Q1 | 189.63 Million USD | -9.77% |
| 2020 FY | -113.45 Million USD | -153.98% |
| 2020 Q4 | -113.45 Million USD | -261.57% |
| 2019 Q4 | 210.17 Million USD | 180.52% |
| 2019 FY | 210.17 Million USD | 147.41% |
| 2019 Q2 | 139.09 Million USD | -30.19% |
| 2019 Q1 | 199.24 Million USD | 134.55% |
| 2019 Q3 | 74.92 Million USD | -46.13% |
| 2018 Q2 | 230.05 Million USD | 2.26% |
| 2018 FY | 84.95 Million USD | 230.46% |
| 2018 Q4 | 84.95 Million USD | -56.67% |
| 2018 Q1 | 224.97 Million USD | 445.49% |
| 2018 Q3 | 196.04 Million USD | -14.78% |
| 2017 Q2 | 69.83 Million USD | 144.0% |
| 2017 Q4 | -65.11 Million USD | -486.41% |
| 2017 FY | -65.11 Million USD | 73.43% |
| 2017 Q1 | -158.72 Million USD | 35.23% |
| 2017 Q3 | 16.85 Million USD | -75.87% |
| 2016 Q3 | -293.72 Million USD | -560.47% |
| 2016 FY | -245.05 Million USD | 41.03% |
| 2016 Q4 | -245.05 Million USD | 16.57% |
| 2016 Q1 | -374.57 Million USD | 9.86% |
| 2016 Q2 | 63.78 Million USD | 117.03% |
| 2015 Q2 | 97.01 Million USD | 146.67% |
| 2015 FY | -415.54 Million USD | -79.37% |
| 2015 Q3 | -150.13 Million USD | -254.76% |
| 2015 Q1 | -207.88 Million USD | 10.27% |
| 2015 Q4 | -415.54 Million USD | -176.78% |
| 2014 Q4 | -231.67 Million USD | -521.77% |
| 2014 FY | -231.67 Million USD | -116.01% |
| 2014 Q2 | -58 Million USD | -131.47% |
| 2014 Q3 | -37.26 Million USD | 35.77% |
| 2014 Q1 | -25.06 Million USD | 76.63% |
| 2013 Q4 | -107.25 Million USD | -4067.85% |
| 2013 FY | -107.25 Million USD | 46.31% |
| 2013 Q3 | 2.7 Million USD | 101.77% |
| 2013 Q2 | -152.7 Million USD | -1265.34% |
| 2013 Q1 | -11.18 Million USD | 94.4% |
| 2012 Q3 | 3.06 Million USD | 131.98% |
| 2012 Q4 | -199.75 Million USD | -6613.11% |
| 2012 Q2 | -9.59 Million USD | -114.61% |
| 2012 Q1 | -4.46 Million USD | 97.23% |
| 2012 FY | -199.75 Million USD | 22.21% |
| 2011 Q1 | 8.08 Million USD | 143.16% |
| 2011 FY | -256.79 Million USD | -1271.42% |
| 2011 Q4 | -161.41 Million USD | -2955.94% |
| 2011 Q3 | -5.28 Million USD | -200.8% |
| 2011 Q2 | 5.24 Million USD | -35.16% |
| 2010 Q3 | -183.23 Million USD | 9.59% |
| 2010 Q4 | -18.72 Million USD | 89.78% |
| 2010 FY | -18.72 Million USD | 44.25% |
| 2010 Q1 | -195.32 Million USD | -481.51% |
| 2010 Q2 | -202.67 Million USD | -3.76% |
| 2009 Q4 | -33.59 Million USD | -788.6% |
| 2009 Q1 | 27.97 Million USD | 150.5% |
| 2009 Q2 | 17.8 Million USD | -36.33% |
| 2009 Q3 | 4.87 Million USD | -72.61% |
| 2009 FY | -33.59 Million USD | 39.35% |
| 2008 Q1 | -28.3 Million USD | -435.52% |
| 2008 FY | -55.38 Million USD | -756.56% |
| 2008 Q4 | -55.38 Million USD | 20.3% |
| 2008 Q3 | -69.48 Million USD | 11.72% |
| 2008 Q2 | -78.7 Million USD | -178.11% |
| 2007 Q1 | 12.37 Million USD | 530.68% |
| 2007 FY | 8.43 Million USD | 329.92% |
| 2007 Q4 | 8.43 Million USD | 144.08% |
| 2007 Q3 | -19.13 Million USD | -308.03% |
| 2007 Q2 | 9.19 Million USD | -25.66% |
| 2006 FY | 1.96 Million USD | -86.89% |
| 2006 Q2 | 22.02 Million USD | 47.91% |
| 2006 Q3 | 24.26 Million USD | 10.17% |
| 2006 Q4 | 1.96 Million USD | -91.91% |
| 2006 Q1 | 14.89 Million USD | -0.53% |
| 2005 FY | 14.97 Million USD | -34.97% |
| 2005 Q2 | 24.79 Million USD | 0.63% |
| 2005 Q3 | 14 Million USD | -43.55% |
| 2005 Q4 | 14.97 Million USD | 6.93% |
| 2005 Q1 | 24.64 Million USD | 7.06% |
| 2004 FY | 23.01 Million USD | 190.02% |
| 2004 Q4 | 23.01 Million USD | 178.51% |
| 2004 Q3 | -29.31 Million USD | -0.61% |
| 2004 Q2 | -29.14 Million USD | -665.61% |
| 2004 Q1 | 5.15 Million USD | 120.15% |
| 2003 Q2 | -29.89 Million USD | 15.02% |
| 2003 FY | -25.57 Million USD | 27.69% |
| 2003 Q1 | -35.17 Million USD | 0.52% |
| 2003 Q3 | -60.27 Million USD | -101.61% |
| 2003 Q4 | -25.57 Million USD | 57.57% |
| 2002 FY | -35.36 Million USD | -53.43% |
| 2002 Q4 | -35.36 Million USD | 55.64% |
| 2002 Q2 | -22.29 Million USD | 53.1% |
| 2002 Q3 | -79.72 Million USD | -257.55% |
| 2002 Q1 | -47.54 Million USD | -106.27% |
| 2001 Q2 | -42.61 Million USD | 44.38% |
| 2001 FY | -23.04 Million USD | 34.08% |
| 2001 Q3 | -11.82 Million USD | 72.25% |
| 2001 Q4 | -23.04 Million USD | -94.91% |
| 2001 Q1 | -76.61 Million USD | -119.11% |
| 2000 Q1 | 2.76 Million USD | 0.0% |
| 2000 Q3 | -20.85 Million USD | 54.96% |
| 2000 FY | -34.96 Million USD | -417.86% |
| 2000 Q2 | -46.31 Million USD | -1776.08% |
| 2000 Q4 | -34.96 Million USD | -67.63% |
| 1999 FY | 11 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| AbCellera Biologics Inc. | -55.94 Million USD | 249.444% |
| Alkermes plc | -166.73 Million USD | 150.138% |
| Agenus Inc. | 274.13 Million USD | 69.505% |
| Alnylam Pharmaceuticals, Inc. | 1.86 Billion USD | 95.529% |
| Aptorum Group Limited | 1.35 Million USD | -6060.366% |
| Ardelyx, Inc. | 34.51 Million USD | -142.232% |
| Arrowhead Pharmaceuticals, Inc. | 4.28 Million USD | -1853.248% |
| Bicycle Therapeutics plc | -481.46 Million USD | 117.363% |
| BioXcel Therapeutics, Inc. | 36.16 Million USD | -131.173% |
| ChromaDex Corporation | -24.04 Million USD | 447.634% |
| Chimerix, Inc. | -25.51 Million USD | 427.621% |
| Corbus Pharmaceuticals Holdings, Inc. | 6.96 Million USD | -1099.743% |
| Caribou Biosciences, Inc. | -23.67 Million USD | 453.081% |
| CRISPR Therapeutics AG | -150.84 Million USD | 155.42% |
| Precision BioSciences, Inc. | -85.41 Million USD | 197.88% |
| Dyadic International, Inc. | -6.37 Million USD | 1410.72% |
| Eton Pharmaceuticals, Inc. | -15.93 Million USD | 624.691% |
| Fortress Biotech, Inc. | 7.66 Million USD | -990.659% |
| Lantern Pharma Inc. | -21.7 Million USD | 485.191% |
| HOOKIPA Pharma Inc. | -110.53 Million USD | 175.63% |
| Inhibikase Therapeutics, Inc. | -8.54 Million USD | 1078.547% |
| Incyte Corporation | -3.17 Billion USD | 102.633% |
| IO Biotech, Inc. | -140.69 Million USD | 159.417% |
| Jaguar Health, Inc. | 29.39 Million USD | -184.437% |
| Novavax, Inc. | -298.29 Million USD | 128.026% |
| Janux Therapeutics, Inc. | 5.33 Million USD | -1466.404% |
| Opthea Limited | 28.15 Million USD | -196.898% |
| Ligand Pharmaceuticals Incorporated | -16.78 Million USD | 597.939% |
| ContextLogic Inc. | -232 Million USD | 136.034% |
| MiMedx Group, Inc. | -33.9 Million USD | 346.597% |
| Pyxis Oncology, Inc. | 10.19 Million USD | -720.0% |
| TransCode Therapeutics, Inc. | -2.31 Million USD | 3708.029% |
| NextCure, Inc. | -6.47 Million USD | 1390.706% |
| Ocuphire Pharma, Inc. | -50.5 Million USD | 265.539% |
| Oncternal Therapeutics, Inc. | -6.37 Million USD | 1410.535% |
| Outlook Therapeutics, Inc. | 12.16 Million USD | -587.307% |
| Vaxcyte, Inc. | -368.22 Million USD | 122.703% |
| PDS Biotechnology Corporation | -32.7 Million USD | 355.585% |
| Madrigal Pharmaceuticals, Inc. | 17.27 Million USD | -383.847% |
| Pharming Group N.V. | 109.8 Million USD | 23.865% |
| Pieris Pharmaceuticals, Inc. | -17.39 Million USD | 580.564% |
| Avidity Biosciences, Inc. | -175.23 Million USD | 147.708% |
| Reviva Pharmaceuticals Holdings, Inc. | -18.51 Million USD | 551.402% |
| Reviva Pharmaceuticals Holdings, Inc. | -18.51 Million USD | 551.402% |
| Sangamo Therapeutics, Inc. | -7.1 Million USD | 1277.451% |
| Sol-Gel Technologies Ltd. | -5.86 Million USD | 1526.604% |
| Acelyrin, Inc. | -216.9 Million USD | 138.542% |
| Salarius Pharmaceuticals, Inc. | -5.61 Million USD | 1590.107% |
| SELLAS Life Sciences Group, Inc. | -1.72 Million USD | 4949.13% |
| Summit Therapeutics Inc. | 34.67 Million USD | -141.1% |
| Sensei Biotherapeutics, Inc. | -6.8 Million USD | 1328.855% |
| Senti Biosciences, Inc. | 1.74 Million USD | -4704.54% |
| Stoke Therapeutics, Inc. | -184.6 Million USD | 145.285% |
| Syros Pharmaceuticals, Inc. | -77.45 Million USD | 207.938% |
| Alaunos Therapeutics, Inc. | -6.06 Million USD | 1479.066% |
| Telomir Pharmaceuticals, Inc. Common Stock | 99.76 Thousand USD | -83692.561% |
| Entrada Therapeutics, Inc. | 628 Thousand USD | -13211.943% |
| VistaGen Therapeutics, Inc. | -117.04 Million USD | 171.424% |
| Wave Life Sciences Ltd. | -168.23 Million USD | 149.692% |
| Sorrento Therapeutics, Inc. | 110.87 Million USD | 24.597% |
| TRACON Pharmaceuticals, Inc. | -7.59 Million USD | 1200.566% |
| Barinthus Biotherapeutics plc | -129.11 Million USD | 164.748% |
| Psyence Biomedical Ltd. | 6.89 Million USD | -1112.529% |
| Phathom Pharmaceuticals, Inc. | -242.36 Million USD | 134.493% |
| Immix Biopharma, Inc. | -17.5 Million USD | 577.441% |
| Keros Therapeutics, Inc. | -316.7 Million USD | 126.397% |
| MEI Pharma, Inc. | -3.7 Million USD | 2356.383% |
| Windtree Therapeutics, Inc. | 12.51 Million USD | -568.204% |
| Xeris Biopharma Holdings, Inc. | 161.74 Million USD | 48.313% |
| Rigel Pharmaceuticals, Inc. | 27.79 Million USD | -200.792% |
| Fortress Biotech, Inc. | 7.66 Million USD | -990.659% |
| Precigen, Inc. | -481 Thousand USD | 17480.249% |
| Clearside Biomedical, Inc. | 14.08 Million USD | -493.701% |
| AlloVir, Inc. | -62.69 Million USD | 233.349% |
| C4 Therapeutics, Inc. | -55.61 Million USD | 250.32% |
| Fate Therapeutics, Inc. | 61.66 Million USD | -35.567% |
| ImmuCell Corporation | 10.99 Million USD | -660.644% |
| IDEAYA Biosciences, Inc. | -154.14 Million USD | 154.234% |
| Onconetix, Inc. | 5.33 Million USD | -1468.039% |
| PureTech Health plc | -167.19 Million USD | 150.0% |
| VYNE Therapeutics Inc. | -30.46 Million USD | 374.455% |
| Elevation Oncology, Inc. | -19.11 Million USD | 537.279% |
| Kintara Therapeutics, Inc. | -4.9 Million USD | 1802.974% |
| Seer, Inc. | -4.24 Million USD | 2071.675% |
| Verrica Pharmaceuticals Inc. | -24.03 Million USD | 447.793% |
| Innoviva, Inc. | 255.56 Million USD | 67.288% |
| Aadi Bioscience, Inc. | -55.86 Million USD | 249.647% |
| ESSA Pharma Inc. | -33.62 Million USD | 348.647% |
| GlycoMimetics, Inc. | -40.98 Million USD | 303.977% |
| GT Biopharma, Inc. | -1.02 Million USD | 8287.953% |
| Inhibrx Biosciences, Inc. | -67.78 Million USD | 223.333% |
| Akebia Therapeutics, Inc. | 61.25 Million USD | -36.473% |
| Catalyst Pharmaceuticals, Inc. | -134.07 Million USD | 162.351% |
| Longboard Pharmaceuticals, Inc. | -13.85 Million USD | 703.342% |
| Orchestra BioMed Holdings, Inc. | -28.87 Million USD | 389.55% |
| Alzamend Neuro, Inc. | -75.33 Thousand USD | 111071.142% |
| Rocket Pharmaceuticals, Inc. | -30.86 Million USD | 370.88% |
| Aptose Biosciences Inc. | -8.19 Million USD | 1120.14% |
| ZyVersa Therapeutics, Inc. | -3.12 Million USD | 2771.733% |
| Soligenix, Inc. | -4.95 Million USD | 1788.324% |
| Century Therapeutics, Inc. | 847 Thousand USD | -9770.012% |
| Kura Oncology, Inc. | -20.11 Million USD | 515.543% |
| TScan Therapeutics, Inc. | -40.92 Million USD | 304.269% |
| Intensity Therapeutics, Inc. | -8.39 Million USD | 1095.463% |
| Ocean Biomedical, Inc. | 1.82 Million USD | -4489.078% |
| CytomX Therapeutics, Inc. | -3.19 Million USD | 2714.92% |
| Autolus Therapeutics plc | -186.59 Million USD | 144.801% |
| Mineralys Therapeutics, Inc. | -49.3 Million USD | 269.558% |
| EyePoint Pharmaceuticals, Inc. | -275.79 Million USD | 130.312% |
| Eterna Therapeutics Inc. | 34.26 Million USD | -143.956% |
| Adaptive Biotechnologies Corporation | 164.36 Million USD | 49.139% |
| GRI Bio, Inc. | -1.79 Million USD | 4759.922% |
| Xenetic Biosciences, Inc. | -8.98 Million USD | 1030.631% |
| Tenaya Therapeutics, Inc. | -33.25 Million USD | 351.373% |
| IGM Biosciences, Inc. | -72.6 Million USD | 215.141% |
| INmune Bio, Inc. | -25.41 Million USD | 428.987% |
| Heron Therapeutics, Inc. | 150.95 Million USD | 44.618% |
| SAB Biotherapeutics, Inc. | -50.65 Million USD | 265.023% |
| Pasithea Therapeutics Corp. | -16.24 Million USD | 614.475% |
| Entero Therapeutics, Inc. | -2.88 Million USD | 2997.787% |
| Milestone Pharmaceuticals Inc. | 38.01 Million USD | -119.911% |
| X4 Pharmaceuticals, Inc. | -41.18 Million USD | 302.984% |
| Atara Biotherapeutics, Inc. | 31.88 Million USD | -162.189% |
| Coherus BioSciences, Inc. | 377.95 Million USD | 77.881% |
| Verastem, Inc. | -37.27 Million USD | 324.258% |
| Abeona Therapeutics Inc. | -9.07 Million USD | 1021.404% |
| Pliant Therapeutics, Inc. | -51.86 Million USD | 261.195% |
| Tonix Pharmaceuticals Holding Corp. | -15.13 Million USD | 652.355% |
| Histogen Inc. | -7.48 Million USD | 1216.589% |
| Aprea Therapeutics, Inc. | -21.6 Million USD | 486.91% |
| Surrozen, Inc. | -32.66 Million USD | 355.936% |
| Organovo Holdings, Inc. | -1.5 Million USD | 5647.379% |
| Lixte Biotechnology Holdings, Inc. | -4.2 Million USD | 2088.801% |
| Ovid Therapeutics Inc. | 18.96 Million USD | -340.918% |
| Panbela Therapeutics, Inc. | 2.61 Million USD | -3095.68% |
| CASI Pharmaceuticals, Inc. | 4.15 Million USD | -1911.526% |
| Cadrenal Therapeutics, Inc. Common Stock | -8.38 Million USD | 1097.465% |
| Centessa Pharmaceuticals plc | -43.44 Million USD | 292.438% |
| Hepion Pharmaceuticals, Inc. | -14.57 Million USD | 673.505% |
| Arcturus Therapeutics Holdings Inc. | -316.78 Million USD | 126.389% |
| BioRestorative Therapies, Inc. | -722.06 Thousand USD | 11677.847% |
| Apollomics, Inc. | -27.39 Million USD | 405.162% |
| Amarin Corporation plc | -191.04 Million USD | 143.76% |
| Mesoblast Limited | 55.96 Million USD | -49.383% |
| Turnstone Biologics Corp. | -14.58 Million USD | 673.224% |
| Kymera Therapeutics, Inc. | -25.29 Million USD | 430.535% |
| Synaptogenix, Inc. | -28.66 Million USD | 391.677% |
| Tiziana Life Sciences Ltd | -936 Thousand USD | 9031.517% |
| Aurinia Pharmaceuticals Inc. | 48.73 Million USD | -71.548% |
| BriaCell Therapeutics Corp. | -862.08 Thousand USD | 9797.259% |
| Monopar Therapeutics Inc. | -7.26 Million USD | 1250.538% |
| Exelixis, Inc. | -73.05 Million USD | 214.441% |
| Better Therapeutics, Inc. | -860 Thousand USD | 9820.814% |
| Nurix Therapeutics, Inc. | -24.01 Million USD | 448.141% |
| Apellis Pharmaceuticals, Inc. | -241.37 Million USD | 134.635% |
| NLS Pharmaceutics AG | 736.06 Thousand USD | -11257.541% |
| Dermata Therapeutics, Inc. | -7.43 Million USD | 1223.924% |
| Aridis Pharmaceuticals, Inc. | 1.25 Million USD | -6566.587% |
| Gritstone bio, Inc. | 39.49 Million USD | -111.697% |
| Jasper Therapeutics, Inc. | -84.1 Million USD | 199.403% |
| TNF Pharmaceuticals, Inc. | -2.63 Million USD | 3276.085% |
| Avid Bioservices, Inc. | 169.72 Million USD | 50.745% |
| Insmed Incorporated | 721.62 Million USD | 88.415% |
| Virpax Pharmaceuticals, Inc. | -9.14 Million USD | 1014.499% |
| MediWound Ltd. | -5.32 Million USD | 1670.819% |
| OmniAb, Inc. | 9.2 Million USD | -808.389% |
| Alector, Inc. | -35.63 Million USD | 334.585% |
| Seres Therapeutics, Inc. | 85.97 Million USD | 2.759% |
| Checkpoint Therapeutics, Inc. | -4.92 Million USD | 1796.408% |
| Viracta Therapeutics, Inc. | 13.23 Million USD | -531.46% |
| Zai Lab Limited | -775 Million USD | 110.787% |
| Revance Therapeutics, Inc. | 340.55 Million USD | 75.452% |
| Aura Biosciences, Inc. | -21.52 Million USD | 488.381% |
| Lyell Immunopharma, Inc. | -82.48 Million USD | 201.357% |
| Immunic, Inc. | -45.34 Million USD | 284.382% |
| Tarsus Pharmaceuticals, Inc. | -193.21 Million USD | 143.267% |
| Veracyte, Inc. | -203.82 Million USD | 141.015% |
| InMed Pharmaceuticals Inc. | 638.29 Million USD | 86.903% |
| FibroGen, Inc. | 56.76 Million USD | -47.267% |
| SeaStar Medical Holding Corporation | 8.9 Million USD | -838.787% |
| Adial Pharmaceuticals, Inc. | -2.82 Million USD | 3057.077% |
| Sonnet BioTherapeutics Holdings, Inc. | -2.07 Million USD | 4137.92% |
| Jazz Pharmaceuticals plc | 4.59 Billion USD | 98.179% |
| Cyclacel Pharmaceuticals, Inc. | -3.34 Million USD | 2602.215% |
| Amylyx Pharmaceuticals, Inc. | -165.96 Million USD | 150.372% |
| TG Therapeutics, Inc. | 17.86 Million USD | -368.027% |
| Galecto, Inc. | -21.21 Million USD | 494.038% |
| Calithera Biosciences, Inc. | -23.78 Million USD | 451.478% |
| Fortrea Holdings Inc. | 1.56 Billion USD | 94.673% |
| KalVista Pharmaceuticals, Inc. | -24.47 Million USD | 441.611% |
| Aptevo Therapeutics Inc. | -11.5 Million USD | 826.506% |
| XBiotech Inc. | -200.02 Million USD | 141.795% |
| Jasper Therapeutics, Inc. | -84.1 Million USD | 199.403% |
| Lyra Therapeutics, Inc. | 4.52 Million USD | -1746.268% |
| Foghorn Therapeutics Inc. | -35.26 Million USD | 337.073% |
| Y-mAbs Therapeutics, Inc. | -77.21 Million USD | 208.264% |
| Theravance Biopharma, Inc. | 5.69 Million USD | -1368.969% |
| Ultragenyx Pharmaceutical Inc. | -170.41 Million USD | 149.056% |
| Metagenomi, Inc. Common Stock | -92.37 Million USD | 190.501% |
| Vaxxinity, Inc. | 10.13 Million USD | -725.099% |
| BioCryst Pharmaceuticals, Inc. | 736.26 Million USD | 88.646% |
| Gain Therapeutics, Inc. | -10.76 Million USD | 876.398% |
| Cartesian Therapeutics, Inc. | -65.95 Million USD | 226.75% |
| NexImmune, Inc. | -3.13 Million USD | 2767.79% |
| Creative Medical Technology Holdings, Inc. | -3.45 Million USD | 2521.283% |
| Marker Therapeutics, Inc. | -15.11 Million USD | 653.216% |
| Regeneron Pharmaceuticals, Inc. | -27.1 Million USD | 408.483% |
| Chemomab Therapeutics Ltd. | -8.97 Million USD | 1031.356% |
| Scopus BioPharma Inc. | -124.57 Thousand USD | 67207.365% |
| RAPT Therapeutics, Inc. | -40.57 Million USD | 306.051% |
| Ainos, Inc. | 4.07 Million USD | -1950.036% |
| Pluri Inc. | 22.82 Million USD | -266.197% |
| Prothena Corporation plc | -608.34 Million USD | 113.742% |
| Adaptimmune Therapeutics plc | -118.75 Million USD | 170.396% |
| Celularity Inc. | 65.19 Million USD | -28.239% |
| Rallybio Corporation | -24.1 Million USD | 446.855% |
| Cue Biopharma, Inc. | -33.81 Million USD | 347.195% |
| MeiraGTx Holdings plc | -40.3 Million USD | 307.431% |
| Omeros Corporation | 331.17 Million USD | 74.757% |
| Humacyte, Inc. | -22.48 Million USD | 471.782% |
| Immunocore Holdings plc | -358.59 Million USD | 123.313% |
| Cocrystal Pharma, Inc. | -24.57 Million USD | 440.179% |
| Cidara Therapeutics, Inc. | -30.9 Million USD | 370.538% |
| Blueprint Medicines Corporation | 702.83 Million USD | 88.105% |
| CalciMedica, Inc. | -5.53 Million USD | 1611.736% |
| Cabaletta Bio, Inc. | -188.22 Million USD | 144.416% |
| Marinus Pharmaceuticals, Inc. | -10.21 Million USD | 918.475% |
| Scholar Rock Holding Corporation | -40.03 Million USD | 308.804% |
| Sana Biotechnology, Inc. | -33.25 Million USD | 351.403% |
| Pulmatrix, Inc. | -10.41 Million USD | 902.525% |
| Elicio Therapeutics, Inc. | -5.97 Million USD | 1498.678% |
| Vigil Neuroscience, Inc. | -38.14 Million USD | 319.178% |
| Intellia Therapeutics, Inc. | -111.4 Million USD | 175.043% |
| Adlai Nortye Ltd. American Depositary Shares | -59.94 Million USD | 239.462% |
| Cytokinetics, Incorporated | 642.37 Million USD | 86.986% |
| Eloxx Pharmaceuticals, Inc. | -5.82 Million USD | 1535.669% |
| Nutriband Inc. | -251.65 Thousand USD | 33319.422% |
| Protara Therapeutics, Inc. | -34.11 Million USD | 345.022% |
| Vor Biopharma Inc. | 4.3 Million USD | -1844.163% |
| Roivant Sciences Ltd. | -6.03 Billion USD | 101.385% |
| Evogene Ltd. | -19.63 Million USD | 525.787% |
| ProKidney Corp. | -56.23 Million USD | 248.657% |
| Applied Therapeutics, Inc. | -48.67 Million USD | 271.76% |
| Hoth Therapeutics, Inc. | -9.23 Million USD | 1005.027% |
| BridgeBio Pharma, Inc. | 1.36 Billion USD | 93.871% |
| CorMedix Inc. | -43.05 Million USD | 294.179% |
| BioLineRx Ltd. | 7.33 Million USD | -1039.572% |
| Tango Therapeutics, Inc. | -27.46 Million USD | 404.384% |
| Galectin Therapeutics Inc. | 46.14 Million USD | -81.158% |
| Atai Life Sciences N.V. | -28.55 Million USD | 392.734% |
| Renovaro Biosciences Inc. | 2.23 Million USD | -3647.945% |
| Aerovate Therapeutics, Inc. | -22.81 Million USD | 466.405% |
| Zentalis Pharmaceuticals, Inc. | 17.73 Million USD | -371.379% |
| Sagimet Biosciences Inc. | -75.07 Million USD | 211.355% |
| MediciNova, Inc. | -50.78 Million USD | 264.618% |
| Praxis Precision Medicines, Inc. | -78.8 Million USD | 206.083% |
| Cardio Diagnostics Holdings, Inc. | -22.49 Thousand USD | 371733.696% |
| GeoVax Labs, Inc. | -6.45 Million USD | 1395.588% |
| Axsome Therapeutics, Inc. | -199.82 Million USD | 141.837% |
| Biomea Fusion, Inc. | -166.57 Million USD | 150.189% |
| PTC Therapeutics, Inc. | -178.97 Million USD | 146.71% |
| Mereo BioPharma Group plc | -51.46 Million USD | 262.426% |
| Cullinan Oncology, Inc. | -94.84 Million USD | 188.144% |
| Syndax Pharmaceuticals, Inc. | -293.75 Million USD | 128.458% |
| Absci Corporation | -72.59 Million USD | 215.153% |
| NRx Pharmaceuticals, Inc. | 4.56 Million USD | -1730.902% |
| 4D Molecular Therapeutics, Inc. | -234.43 Million USD | 135.659% |
| Dyne Therapeutics, Inc. | -94.21 Million USD | 188.736% |
| Kiniksa Pharmaceuticals, Ltd. | -95.69 Million USD | 187.359% |
| Ventyx Biosciences, Inc. | -39.07 Million USD | 313.956% |
| Allakos Inc. | -24.97 Million USD | 434.731% |
| Imunon, Inc. | -4.21 Million USD | 2083.909% |
| Fulcrum Therapeutics, Inc. | -14.74 Million USD | 667.08% |
| Corcept Therapeutics Incorporated | -135.4 Million USD | 161.742% |
| BioAtla, Inc. | -109.01 Million USD | 176.689% |
| NLS Pharmaceutics AG | 736.06 Thousand USD | -11257.541% |
| Bio-Path Holdings, Inc. | -939 Thousand USD | 9002.982% |
| Allogene Therapeutics, Inc. | 11.96 Million USD | -598.638% |
| Larimar Therapeutics, Inc. | -21.2 Million USD | 494.279% |
| XOMA Corporation | -29 Million USD | 388.272% |
| Kezar Life Sciences, Inc. | -16.56 Million USD | 604.825% |
| Cara Therapeutics, Inc. | -9.01 Million USD | 1027.229% |
| aTyr Pharma, Inc. | -7.44 Million USD | 1222.285% |
| Aligos Therapeutics, Inc. | -124.63 Million USD | 167.075% |
| Akero Therapeutics, Inc. | -208.16 Million USD | 140.16% |
| Viridian Therapeutics, Inc. | -81.77 Million USD | 202.226% |
| Eliem Therapeutics, Inc. | -92.76 Million USD | 190.121% |
| EyeGate Pharmaceuticals, Inc. | -859.18 Thousand USD | 9830.046% |
| Akari Therapeutics, Plc | -3.84 Million USD | 2274.226% |
| Tevogen Bio Holdings Inc. | 1.62 Million USD | -5051.243% |
| Halozyme Therapeutics, Inc. | 1.38 Billion USD | 93.946% |
| Lexaria Bioscience Corp. | -1.18 Million USD | 7136.153% |
| UroGen Pharma Ltd. | 4.39 Million USD | -1803.872% |
| Sutro Biopharma, Inc. | 113.48 Million USD | 26.332% |
| ZIVO Bioscience, Inc. | 71.96 Thousand USD | -116071.035% |
| Orgenesis Inc. | 21.78 Million USD | -283.763% |
| Entera Bio Ltd. | -10.62 Million USD | 886.518% |
| GH Research PLC | -78.07 Million USD | 207.073% |
| Lisata Therapeutics, Inc. | -22.28 Million USD | 475.085% |
| Reneo Pharmaceuticals, Inc. | -26.65 Million USD | 413.586% |
| Xencor, Inc. | 29.64 Million USD | -182.01% |
| 60 Degrees Pharmaceuticals, Inc. | -1.96 Million USD | 4344.009% |
| Replimune Group, Inc. | 1.41 Million USD | -5820.609% |
| Coeptis Therapeutics Holdings, Inc. | -244.9 Thousand USD | 34234.859% |
| Vanda Pharmaceuticals Inc. | -126.41 Million USD | 166.13% |
| Lexaria Bioscience Corp. | -1.18 Million USD | 7136.153% |
| Portage Biotech Inc. | -4.98 Million USD | 1778.358% |
| Cardio Diagnostics Holdings, Inc. | -22.49 Thousand USD | 371733.696% |
| Olema Pharmaceuticals, Inc. | -66.12 Million USD | 226.431% |
| OncoCyte Corporation | -6.56 Million USD | 1373.792% |
| Qualigen Therapeutics, Inc. | 897.41 Thousand USD | -9215.555% |
| Processa Pharmaceuticals, Inc. | -4.55 Million USD | 1935.065% |
| Purple Biotech Ltd. | -14.13 Million USD | 691.307% |
| CollPlant Biotechnologies Ltd. | -23.75 Million USD | 451.907% |
| scPharmaceuticals Inc. | -6.54 Million USD | 1377.296% |
| ProMIS Neurosciences, Inc. | -16.69 Million USD | 600.828% |
| HilleVax, Inc. | -165.48 Million USD | 150.518% |
| NeuroSense Therapeutics Ltd. | -2.53 Million USD | 3393.893% |
| Tharimmune, Inc. | -10.93 Million USD | 864.484% |
| Genprex, Inc. | -6.73 Million USD | 1340.778% |
| Neumora Therapeutics, Inc. Common Stock | -368.8 Million USD | 122.667% |
| Atossa Therapeutics, Inc. | -88.46 Million USD | 194.505% |
| XTL Biopharmaceuticals Ltd. | -1.4 Million USD | 6067.095% |
| Virios Therapeutics, Inc. | -3.31 Million USD | 2620.361% |
| OKYO Pharma Limited | -826.84 Thousand USD | 10210.564% |
| Savara Inc. | 153 Thousand USD | -54539.869% |
| Curis, Inc. | -23.88 Million USD | 449.977% |
| Daré Bioscience, Inc. | -5.15 Million USD | 1720.792% |
| Carmell Therapeutics Corporation | -776.01 Thousand USD | 10872.9% |
| Titan Pharmaceuticals, Inc. | -6.2 Million USD | 1446.633% |
| Achieve Life Sciences, Inc. | 1.18 Million USD | -6954.768% |
| BeiGene, Ltd. | -2.25 Billion USD | 103.71% |
| Kiromic BioPharma, Inc. | 12.33 Million USD | -577.546% |
| Revolution Medicines, Inc. Warrant | -608.2 Million USD | 113.745% |
| Protagonist Therapeutics, Inc. | -185.58 Million USD | 145.046% |
| Erasca, Inc. | -37.21 Million USD | 324.632% |
| bluebird bio, Inc. | 108.57 Million USD | 23.001% |
| Protagenic Therapeutics, Inc. | -1.28 Million USD | 6591.145% |
| BioMarin Pharmaceutical Inc. | 378.74 Million USD | 77.928% |
| DBV Technologies S.A. | -126.98 Million USD | 165.833% |
| Protagenic Therapeutics, Inc. | -1.28 Million USD | 6591.145% |
| Moderna, Inc. | -2.9 Billion USD | 102.876% |
| Vincerx Pharma, Inc. | -10.35 Million USD | 907.564% |
| Fresh Tracks Therapeutics, Inc. | -10.86 Million USD | 869.222% |
| Molecular Templates, Inc. | 707 Thousand USD | -11724.47% |
| Acrivon Therapeutics, Inc. Common Stock | -31.37 Million USD | 366.485% |
| Travere Therapeutics, Inc. | 346.6 Million USD | 75.881% |
| Monte Rosa Therapeutics, Inc. | -82.06 Million USD | 201.873% |
| Spruce Biosciences, Inc. | -91.73 Million USD | 191.136% |
| Celldex Therapeutics, Inc. | -32.27 Million USD | 359.045% |
| Cogent Biosciences, Inc. | -34.37 Million USD | 343.19% |
| MacroGenics, Inc. | -66.98 Million USD | 224.803% |
| RenovoRx, Inc. | -1.17 Million USD | 7226.939% |
| Adicet Bio, Inc. | -138.78 Million USD | 160.235% |
| Prime Medicine, Inc. | -27.94 Million USD | 399.198% |
| Aditxt, Inc. | 18.12 Million USD | -361.341% |
| Adagene Inc. | -87.62 Million USD | 195.403% |
| Estrella Immunopharma, Inc. | -4.16 Million USD | 2106.973% |
| Quantum-Si incorporated | -118.55 Million USD | 170.514% |
| Maravai LifeSciences Holdings, Inc. | 36 Million USD | -132.187% |
| Acurx Pharmaceuticals, Inc. | -7.47 Million USD | 1218.503% |
| Voyager Therapeutics, Inc. | -48.5 Million USD | 272.337% |
| SciSparc Ltd. | -2.06 Million USD | 4148.378% |
| Vericel Corporation | 1.27 Million USD | -6446.515% |
| Revelation Biosciences, Inc. | -11.99 Million USD | 797.14% |
| Minerva Neurosciences, Inc. | 41 Million USD | -103.879% |
| Generation Bio Co. | 31.44 Million USD | -165.832% |
| Astria Therapeutics, Inc. | -175.36 Million USD | 147.672% |
| Black Diamond Therapeutics, Inc. | -30.92 Million USD | 370.346% |
| Arcutis Biotherapeutics, Inc. | 116.59 Million USD | 28.298% |
| Invivyd, Inc. | -198.47 Million USD | 142.12% |
| Relay Therapeutics, Inc. | -90.27 Million USD | 192.61% |
| Quoin Pharmaceuticals, Ltd. | -2.39 Million USD | 3586.65% |
| Spero Therapeutics, Inc. | -70.79 Million USD | 218.094% |
| Artelo Biosciences, Inc. | -6.82 Million USD | 1324.894% |
| 2seventy bio, Inc. | 181.71 Million USD | 53.994% |
| ADMA Biologics, Inc. | 90.06 Million USD | 7.18% |
| Clene Inc. | 3.34 Million USD | -2402.964% |
| Capricor Therapeutics, Inc. | -9.08 Million USD | 1020.42% |
| Boundless Bio, Inc. Common Stock | -21.51 Million USD | 488.634% |
| GeoVax Labs, Inc. | -6.45 Million USD | 1395.588% |
| Recursion Pharmaceuticals, Inc. | -344.12 Million USD | 124.293% |
| Citius Pharmaceuticals, Inc. | -25.99 Million USD | 421.539% |
| Contineum Therapeutics, Inc. Class A Common Stock | 177.66 Million USD | 52.946% |
| Relmada Therapeutics, Inc. | -4.09 Million USD | 2143.203% |
| Finch Therapeutics Group, Inc. | 5 Million USD | -1571.311% |
| ALX Oncology Holdings Inc. | -5.2 Million USD | 1704.895% |
| Vir Biotechnology, Inc. | -130.3 Million USD | 164.157% |
| Evaxion Biotech A/S | 5.28 Million USD | -1481.265% |
| Ocular Therapeutix, Inc. | -112.56 Million USD | 174.265% |
| Verve Therapeutics, Inc. | -131.27 Million USD | 163.683% |
| Trevena, Inc. | 2.25 Million USD | -3602.347% |
| Surrozen, Inc. | -32.66 Million USD | 355.936% |
| Tyra Biosciences, Inc. | -51.51 Million USD | 262.297% |
| Cingulate Inc. | 3.08 Million USD | -2611.891% |
| Galmed Pharmaceuticals Ltd. | -2.93 Million USD | 2946.408% |
| Unity Biotechnology, Inc. | 7.18 Million USD | -1063.197% |
| Tenax Therapeutics, Inc. | -9.29 Million USD | 999.763% |
| Terns Pharmaceuticals, Inc. | -79.32 Million USD | 205.391% |
| ACADIA Pharmaceuticals Inc. | -131.45 Million USD | 163.597% |
| Connect Biopharma Holdings Limited | -105.54 Million USD | 179.209% |
| Clearmind Medicine Inc. | -3.94 Million USD | 2220.383% |
| Kronos Bio, Inc. | -36.05 Million USD | 331.872% |
| Bolt Biotherapeutics, Inc. | 9.4 Million USD | -788.5% |
| CERo Therapeutics Holdings, Inc. | 1.45 Million USD | -5633.314% |
| Viking Therapeutics, Inc. | -54.25 Million USD | 254.082% |
| Statera Biopharma, Inc. | 14.41 Million USD | -479.888% |
| ImmunityBio, Inc. | 618.22 Million USD | 86.478% |
| Korro Bio, Inc. | -132.94 Million USD | 162.883% |
| Kineta, Inc. | -4.54 Million USD | 1940.982% |
| BioVie Inc. | -17.73 Million USD | 571.449% |
| Codexis, Inc. | -43.27 Million USD | 293.199% |
| Celularity Inc. | 65.19 Million USD | -28.239% |
| Crinetics Pharmaceuticals, Inc. | -3.16 Million USD | 2738.025% |
| Celcuity Inc. | 6.78 Million USD | -1132.386% |
| Virax Biolabs Group Limited | -3.36 Million USD | 2584.41% |
| Cibus, Inc. | -8.07 Million USD | 1134.897% |
| Eledon Pharmaceuticals, Inc. | -4.22 Million USD | 2076.803% |
| eFFECTOR Therapeutics, Inc. | 4.57 Million USD | -1729.3% |
| IN8bio, Inc. | -16.38 Million USD | 610.092% |
| Kodiak Sciences Inc. | -103.87 Million USD | 180.48% |
| Annexon, Inc. | -193.75 Million USD | 143.147% |
| Adverum Biotechnologies, Inc. | 36 Thousand USD | -232119.444% |
| Assembly Biosciences, Inc. | -17.49 Million USD | 577.736% |
| Avalo Therapeutics, Inc. | -3.51 Million USD | 2479.704% |
| Ionis Pharmaceuticals, Inc. | 1.05 Billion USD | 92.07% |
| Eyenovia, Inc. | 1.25 Million USD | -6541.683% |
| Puma Biotechnology, Inc. | 26.9 Million USD | -210.719% |
| Conduit Pharmaceuticals Inc. | -3.24 Million USD | 2677.829% |
| Xilio Therapeutics, Inc. | -33.24 Million USD | 351.448% |
| Arcellx, Inc. | -296.95 Million USD | 128.152% |
| Cardiff Oncology, Inc. | -19.5 Million USD | 528.581% |
| Enanta Pharmaceuticals, Inc. | -58.87 Million USD | 241.994% |
| Regulus Therapeutics Inc. | -20.72 Million USD | 503.334% |
| Moolec Science SA | 117.61 Thousand USD | -70977.915% |
| Acumen Pharmaceuticals, Inc. | -38.39 Million USD | 317.711% |
| Geron Corporation | 14.76 Million USD | -466.351% |
| LAVA Therapeutics N.V. | -37.91 Million USD | 320.473% |
| Royalty Pharma plc | 5.65 Billion USD | 98.523% |
| Atea Pharmaceuticals, Inc. | -141.42 Million USD | 159.114% |
| Greenwich LifeSciences, Inc. | -6.98 Million USD | 1296.079% |
| TFF Pharmaceuticals, Inc. | -5.36 Million USD | 1658.851% |
| Mersana Therapeutics, Inc. | -140.73 Million USD | 159.403% |
| Humacyte, Inc. | -22.48 Million USD | 471.782% |
| Structure Therapeutics Inc. | -124.33 Million USD | 167.235% |
| 89bio, Inc. | -289.05 Million USD | 128.922% |
| PMV Pharmaceuticals, Inc. | -25.24 Million USD | 431.19% |
| Avenue Therapeutics, Inc. | -1.78 Million USD | 4788.671% |
| Genelux Corporation | -6.89 Million USD | 1311.755% |
| Trevi Therapeutics, Inc. | -31.05 Million USD | 369.162% |
| Notable Labs, Ltd. | -9.77 Million USD | 955.145% |
| Liquidia Corporation | -80.17 Million USD | 204.269% |
| Mustang Bio, Inc. | -3.73 Million USD | 2337.661% |
| Immunovant, Inc. | -635.22 Million USD | 113.16% |
| Quantum-Si incorporated | -118.55 Million USD | 170.514% |
| Arbutus Biopharma Corporation | -17.56 Million USD | 575.968% |
| DiaMedica Therapeutics Inc. | -4.14 Million USD | 2117.837% |
| Vera Therapeutics, Inc. | 8.02 Million USD | -941.473% |
| Acasti Pharma Inc. | -23 Million USD | 463.395% |
| MiNK Therapeutics, Inc. | -3.36 Million USD | 2582.724% |
| Pasithea Therapeutics Corp. | -16.24 Million USD | 614.475% |
| Xenon Pharmaceuticals Inc. | -137.74 Million USD | 160.693% |
| Elevai Labs, Inc. Common Stock | -3.11 Million USD | 2782.583% |
| NeuroBo Pharmaceuticals, Inc. | -22.23 Million USD | 476.03% |
| Tempest Therapeutics, Inc. | -18.56 Million USD | 550.207% |
| Soleno Therapeutics, Inc. | -169.27 Million USD | 149.386% |
| PepGen Inc. | -60.67 Million USD | 237.793% |
| Moleculin Biotech, Inc. | -22.97 Million USD | 463.854% |
| United Therapeutics Corporation | -507.7 Million USD | 116.466% |
| Nuvectis Pharma, Inc. | -19.12 Million USD | 537.096% |
| Solid Biosciences Inc. | -47.75 Million USD | 275.076% |
| BriaCell Therapeutics Corp. | -862.08 Thousand USD | 9797.259% |
| Immuneering Corporation | -54.94 Million USD | 252.156% |
| Lixte Biotechnology Holdings, Inc. | -4.2 Million USD | 2088.801% |
| Silo Pharma, Inc. | -3.52 Million USD | 2472.069% |
| Belite Bio, Inc | -87.27 Million USD | 195.792% |
| XOMA Corporation | -29 Million USD | 388.272% |
| ARS Pharmaceuticals, Inc. | -70.69 Million USD | 218.25% |
| Bionomics Limited | 227 Million USD | 63.174% |
| Apogee Therapeutics, Inc. | -116.28 Million USD | 171.893% |
| Alpha Tau Medical Ltd. | -2.53 Million USD | 3400.395% |
| uniQure N.V. | -102.95 Million USD | 181.203% |
| Cassava Sciences, Inc. | -121.13 Million USD | 169.013% |
| Estrella Immunopharma, Inc. | -4.16 Million USD | 2106.973% |
| Poseida Therapeutics, Inc. | 40.95 Million USD | -104.144% |
| Forte Biosciences, Inc. | -11.96 Million USD | 798.93% |
| Anebulo Pharmaceuticals, Inc. | -3.09 Million USD | 2801.797% |
| Enlivex Therapeutics Ltd. | 106 Thousand USD | -78766.981% |
| Conduit Pharmaceuticals Inc. | -3.24 Million USD | 2677.829% |
| SeaStar Medical Holding Corporation | 8.9 Million USD | -838.787% |
| FibroBiologics, Inc. Common Stock | -7.41 Million USD | 1227.279% |
| Altimmune, Inc. | -134.48 Million USD | 162.161% |
| Amicus Therapeutics, Inc. | 198.06 Million USD | 57.792% |
| Alpha Tau Medical Ltd. | -2.53 Million USD | 3400.395% |
| Compugen Ltd. | -12.9 Million USD | 747.853% |
| Peak Bio, Inc. | 10.34 Million USD | -708.489% |
| Zevra Therapeutics, Inc. | -283 Thousand USD | 29640.283% |
| Benitec Biopharma Inc. | -50.58 Million USD | 265.274% |
| Spyre Therapeutics, Inc. | -104.33 Million USD | 180.123% |
| NKGen Biotech, Inc. Common Stock | 19.64 Million USD | -325.548% |
| Zura Bio Limited | -99.8 Million USD | 183.761% |
| PolyPid Ltd. | 6.17 Million USD | -1254.927% |
| Aileron Therapeutics, Inc. | 74.12 Million USD | -12.789% |
| NKGen Biotech, Inc. Warrants | 19.64 Million USD | -325.548% |
| Instil Bio, Inc. | 75.35 Million USD | -10.936% |
| argenx SE | -2.02 Billion USD | 104.121% |
| Immunome, Inc. | -97.02 Million USD | 186.159% |
| Compass Therapeutics, Inc. | -22.49 Million USD | 471.634% |
| Verona Pharma plc | -220.44 Million USD | 137.923% |
| enGene Holdings Inc. Warrants | -71.74 Million USD | 216.526% |
| Shattuck Labs, Inc. | -121.42 Million USD | 168.849% |
| CervoMed Inc. | -7.79 Million USD | 1172.766% |
| LENZ Therapeutics, Inc. | -185.49 Million USD | 145.067% |
| Plus Therapeutics, Inc. | -4.37 Million USD | 2011.708% |
| Dianthus Therapeutics, Inc. | -131.73 Million USD | 163.458% |
| Moolec Science SA | 117.61 Thousand USD | -70977.915% |
| Enveric Biosciences, Inc. | -2.28 Million USD | 3753.839% |
| Inovio Pharmaceuticals, Inc. | 15.89 Million USD | -425.833% |
| AnaptysBio, Inc. | -18.15 Million USD | 560.575% |
| Design Therapeutics, Inc. | -18.15 Million USD | 560.601% |
| Leap Therapeutics, Inc. | -70.38 Million USD | 218.781% |
| NeurAxis, Inc. | 145.7 Thousand USD | -57277.488% |
| Seelos Therapeutics, Inc. | 11.23 Million USD | -644.293% |
| Lumos Pharma, Inc. | -28.49 Million USD | 393.402% |
| Achilles Therapeutics plc | -126.92 Million USD | 165.865% |
| enGene Holdings Inc. Common Stock | -71.74 Million USD | 216.526% |
| 180 Life Sciences Corp. | -655.73 Thousand USD | 12848.997% |
| Opiant Pharmaceuticals, Inc. | -20.77 Million USD | 502.425% |
| CERo Therapeutics Holdings, Inc. | 1.45 Million USD | -5633.314% |
| Nutriband Inc. | -251.65 Thousand USD | 33319.422% |
| ORIC Pharmaceuticals, Inc. | -13.17 Million USD | 734.72% |
| CG Oncology, Inc. Common stock | -7.44 Million USD | 1223.642% |
| Fractyl Health, Inc. Common Stock | 340.19 Million USD | 75.426% |
| Rani Therapeutics Holdings, Inc. | 23.73 Million USD | -252.218% |
| MoonLake Immunotherapeutics | -447.47 Million USD | 118.683% |
| Palisade Bio, Inc. | -12.06 Million USD | 793.02% |
| Tourmaline Bio, Inc. | -140.31 Million USD | 159.581% |
| Beam Therapeutics Inc. | -262.72 Million USD | 131.82% |
| Neurogene Inc. | -131.95 Million USD | 163.354% |
| Mirum Pharmaceuticals, Inc. | 21.81 Million USD | -283.2% |
| AEON Biopharma, Inc. | -4.88 Million USD | 1813.094% |
| CARGO Therapeutics, Inc. Common Stock | -377.19 Million USD | 122.164% |
| Sesen Bio, Inc. | -112.55 Million USD | 174.275% |
| Enliven Therapeutics, Inc. | -99.86 Million USD | 183.716% |
| Kiora Pharmaceuticals, Inc. | -2.34 Million USD | 3660.748% |
| Iovance Biotherapeutics, Inc. | -39.02 Million USD | 314.214% |
| Taysha Gene Therapies, Inc. | -83.28 Million USD | 200.381% |
| Athira Pharma, Inc. | -88.99 Million USD | 193.933% |
| Vaccinex, Inc. | -1.28 Million USD | 6590.606% |
| HCW Biologics Inc. | 2.85 Million USD | -2826.443% |
| XOMA Corporation | -29 Million USD | 388.272% |
| Nektar Therapeutics | 210.24 Million USD | 60.236% |
| Arvinas, Inc. | -313.8 Million USD | 126.641% |
| Tevogen Bio Holdings Inc. | 1.62 Million USD | -5051.243% |
| Merus N.V. | -192.88 Million USD | 143.342% |
| Omega Therapeutics, Inc. | 59.98 Million USD | -39.367% |
| Quince Therapeutics, Inc. | -6.93 Million USD | 1304.944% |
| Rezolute, Inc. | -68.16 Million USD | 222.637% |
| Clene Inc. | 3.34 Million USD | -2402.964% |
| Indaptus Therapeutics, Inc. | -13.18 Million USD | 733.95% |
| BeyondSpring Inc. | -13.75 Million USD | 707.772% |
| Synlogic, Inc. | -6.68 Million USD | 1350.546% |
| Allarity Therapeutics, Inc. | 1.13 Million USD | -7272.046% |
| Phio Pharmaceuticals Corp. | -8.45 Million USD | 1088.752% |
| Peak Bio, Inc. | 10.34 Million USD | -708.489% |
| Werewolf Therapeutics, Inc. | -82.42 Million USD | 201.43% |
| Krystal Biotech, Inc. | -350.23 Million USD | 123.869% |
| Karyopharm Therapeutics Inc. | 124.12 Million USD | 32.649% |
| SpringWorks Therapeutics, Inc. | -168.99 Million USD | 149.468% |
| Lipella Pharmaceuticals Inc. | -3.15 Million USD | 2747.931% |
| MannKind Corporation | 143.89 Million USD | 41.904% |
| Ikena Oncology, Inc. | -109.15 Million USD | 176.587% |
| Cyclerion Therapeutics, Inc. | -7.57 Million USD | 1204.2% |
| Gyre Therapeutics, Inc. | -33.1 Million USD | 352.565% |
| Gossamer Bio, Inc. | 180.35 Million USD | 53.648% |
| CohBar, Inc. | -5.93 Million USD | 1509.59% |
| Cognition Therapeutics, Inc. | -29.74 Million USD | 381.024% |
| NRx Pharmaceuticals, Inc. | 4.56 Million USD | -1730.902% |
| Legend Biotech Corporation | -949.39 Million USD | 108.805% |
| Mural Oncology plc | -255.84 Million USD | 132.676% |
| Biora Therapeutics, Inc. | 32.21 Million USD | -159.503% |
| PaxMedica, Inc. Common Stock | -4.71 Million USD | 1874.684% |
| Disc Medicine, Inc. | -358.28 Million USD | 123.333% |
| Champions Oncology, Inc. | 4.81 Million USD | -1637.303% |
| REGENXBIO Inc. | 54.76 Million USD | -52.642% |
| Ensysce Biosciences, Inc. | -268.9 Thousand USD | 31188.443% |
| Anavex Life Sciences Corp. | -151.02 Million USD | 155.355% |
| Cellectar Biosciences, Inc. | -9.01 Million USD | 1027.64% |
| Edgewise Therapeutics, Inc. | -80.68 Million USD | 203.614% |
| Vaxart, Inc. | -8.24 Million USD | 1114.428% |
| PharmaCyte Biotech, Inc. | -50.17 Million USD | 266.598% |
| Aldeyra Therapeutics, Inc. | -127.16 Million USD | 165.74% |
| Cellectis S.A. | -43.85 Million USD | 290.626% |
| Longeveron Inc. | -2.9 Million USD | 2974.794% |
| Repare Therapeutics Inc. | -107.85 Million USD | 177.508% |
| Sarepta Therapeutics, Inc. | 968.37 Million USD | 91.367% |
| Inozyme Pharma, Inc. | 12 Million USD | -596.426% |
| Revolution Medicines, Inc. | -608.2 Million USD | 113.745% |
| Nymox Pharmaceutical Corporation | -1.23 Million USD | 6896.667% |
| Third Harmonic Bio, Inc. | -265.11 Million USD | 131.533% |
| ArriVent BioPharma, Inc. Common Stock | -150.07 Million USD | 155.706% |
| AN2 Therapeutics, Inc. | -15.64 Million USD | 634.281% |
| Anixa Biosciences, Inc. | -740 Thousand USD | 11397.162% |
| Vertex Pharmaceuticals Incorporated | -9.56 Billion USD | 100.874% |
| Denali Therapeutics Inc. | -74.86 Million USD | 211.666% |
| Revelation Biosciences, Inc. | -11.99 Million USD | 797.14% |
| Veru Inc. | 4.77 Million USD | -1648.944% |
| Corvus Pharmaceuticals, Inc. | -11.24 Million USD | 843.367% |
| Cingulate Inc. | 3.08 Million USD | -2611.891% |
| Passage Bio, Inc. | 4.58 Million USD | -1723.315% |
| Context Therapeutics Inc. | -14.44 Million USD | 678.547% |
| Exicure, Inc. | 5.84 Million USD | -1329.287% |
| Day One Biopharmaceuticals, Inc. | -230.37 Million USD | 136.288% |
| Oramed Pharmaceuticals Inc. | -39.57 Million USD | 311.269% |
| Scinai Immunotherapeutics Ltd. | 15.69 Million USD | -432.783% |
| Rhythm Pharmaceuticals, Inc. | -58.82 Million USD | 242.124% |
| Nuvalent, Inc. | -335.38 Million USD | 124.926% |
| ABVC BioPharma, Inc. | 1.73 Million USD | -4720.217% |
| Carisma Therapeutics, Inc. | -74.48 Million USD | 212.241% |
| Unicycive Therapeutics, Inc. | -8.89 Million USD | 1040.371% |
| OmniAb, Inc. | 9.2 Million USD | -808.389% |
| Anew Medical, Inc. | 1.43 Million USD | -5736.024% |
| Fennec Pharmaceuticals Inc. | 16.38 Million USD | -410.318% |
| Lipocine Inc. | -4.75 Million USD | 1858.279% |
| Lexeo Therapeutics, Inc. Common Stock | -109.82 Million USD | 176.118% |
| Nautilus Biotechnology, Inc. | 15.23 Million USD | -448.874% |
| SAB Biotherapeutics, Inc. | -50.65 Million USD | 265.023% |
| G1 Therapeutics, Inc. | 24.89 Million USD | -235.847% |
| Bellerophon Therapeutics, Inc. | -6.72 Million USD | 1343.848% |
| Sage Therapeutics, Inc. | -65.82 Million USD | 226.998% |
| Ocugen, Inc. | -32.52 Million USD | 357.062% |
| Mind Medicine (MindMed) Inc. | -85.57 Million USD | 197.691% |
| Q32 Bio Inc. | -37.94 Million USD | 320.299% |
| Brainstorm Cell Therapeutics Inc. | -628 Thousand USD | 13411.943% |
| Alumis Inc. Common Stock | -13.52 Million USD | 717.924% |
| Equillium, Inc. | -22.39 Million USD | 473.343% |
| Kyverna Therapeutics, Inc. | -25.56 Million USD | 426.967% |
| Coya Therapeutics, Inc. | -32.62 Million USD | 356.228% |
| CNS Pharmaceuticals, Inc. | -247.91 Thousand USD | 33820.832% |
| Galera Therapeutics, Inc. | 134.04 Million USD | 37.632% |
| Evelo Biosciences, Inc. | 3.19 Million USD | -2514.103% |
| Comera Life Sciences Holdings, Inc. | 328.44 Thousand USD | -25353.278% |
| Dominari Holdings Inc. | 195 Thousand USD | -42771.282% |
| Edesa Biotech, Inc. | -5.26 Million USD | 1687.249% |
| vTv Therapeutics Inc. | -8.91 Million USD | 1037.524% |
| Bio-Techne Corporation | 267.74 Million USD | 68.777% |
| Agios Pharmaceuticals, Inc. | -16.2 Million USD | 615.757% |
| Harmony Biosciences Holdings, Inc. | -118.09 Million USD | 170.79% |
| Prelude Therapeutics Incorporated | -8.4 Million USD | 1094.871% |
| Candel Therapeutics, Inc. | -12.65 Million USD | 760.809% |
| iTeos Therapeutics, Inc. | -245.11 Million USD | 134.105% |
| Nkarta, Inc. | 57.29 Million USD | -45.9% |
| BioCardia, Inc. | 212 Thousand USD | -39333.491% |
| Iterum Therapeutics plc | 13.43 Million USD | -522.109% |